Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00163423
Status:
COMPLETED
Last Update Posted:
2016-12-08
First Post:
2005-09-12
Brief Title:
Efficacy of Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma 12 to 75 y BY9010M1-142
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Comparison of Ciclesonide 80 mcg Once Daily in the Evening and Fluticasone Propionate 100 mcg Twice Daily in Patients With Mild to Moderate Asthma
Status:
COMPLETED
Status Verified Date:
2016-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to compare the efficacy of ciclesonide versus fluticasone propionate on lung function time to first asthma exacerbation asthma symptoms use of rescue medication and quality of life in patients with mild to moderate asthma Ciclesonide will be inhaled at one dose level once daily fluticasone propionate will be inhaled at one dose level twice daily The study duration consists of a baseline period 2 to 4 weeks and a treatment period 24 weeks The study will provide further data on safety and tolerability of ciclesonide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None